Bibliographic citations
Farfan, R., Ulloque, J. (2019). Factores Asociados al Tamizaje para Virus de Hepatitis C en Pacientes Viviendo con VIH en dos Hospitales de Lima, 2016-2017 [Tesis, Universidad Peruana de Ciencias Aplicadas (UPC)]. http://hdl.handle.net/10757/648652
Farfan, R., Ulloque, J. Factores Asociados al Tamizaje para Virus de Hepatitis C en Pacientes Viviendo con VIH en dos Hospitales de Lima, 2016-2017 [Tesis]. PE: Universidad Peruana de Ciencias Aplicadas (UPC); 2019. http://hdl.handle.net/10757/648652
@misc{renati/386385,
title = "Factores Asociados al Tamizaje para Virus de Hepatitis C en Pacientes Viviendo con VIH en dos Hospitales de Lima, 2016-2017",
author = "Ulloque Echevarría, Jorge Luis",
publisher = "Universidad Peruana de Ciencias Aplicadas (UPC)",
year = "2019"
}
Introduction: The Human Immunodeficiency virus (HIV) infection is a public health problem that has been intensifying because of the co-infection with Hepatitis C virus (HCV), which increases morbi-mortality. Therefore, screening its presence is essential in HIV patients. There is scarce information about HCV screening among HIV patients in Peru. Methods: Analytic cross-sectional study using medical charts of patients ≥18 years old attended for the first time due to HIV at two public hospitals in Lima, Peru, 2016-2017. Prevalence of screening (having recorded any test for HCV in medical records) was calculated according to the variables of interest. Generalized lineal models, Poisson family with robust variances were used to obtain crude and adjusted prevalence ratios (aPR). Results: The sample of 571 patients had a median age of 31 years (RIQ: 25-41), 87.7% were <50 years, and males (80.2%) predominated. 350 (61.3%) had HCV screening, of which three (0.86%) were positive. The multivariate model found association with hospital, having diagnostic tests for Hepatitis B virus (HBV) and register of transaminase values. When adjusted for hospital on a multilevel model, association was found with male sex (aPR: 1.12; 95%CI 1.04-1.20), age ≥50 (aPR: 0.86; 95%CI 0.85-0.87), use of antiretrovirals (aPR: 0.83; 95%CI 0.77-0.89), and having tests for HBV (aPR: 7.19; 95%CI 5.07-10.19). Conclusions: Male sex and having tests for HBV were associated with higher prevalence of screening for HCV; while age ≥50 and antiretroviral use were associated with lower prevalence.
This item is licensed under a Creative Commons License